tbuckley/cabot-search huggingface dataset:
Abstract 4785: Comparative proteomic analysis of MCF7 and SKBR3 breast cancer cell lines
Authors: Zahra Mojtahedi, Nasrollah Erfani, Abbas Ghaderi
Journal: Cancer Research (2012)

Abstract Differentially expressed proteins among cancer cell lines fit each cell line as a model for gaining knowledge of heterogeneity in cancer. The aim of our study was to identify differentially expressed proteins between MCF7 (ER+, low HER2 expression) and SKBR3 (ER-, high HER2 expression) cell lines by a proteomic approach. Moreover, a number of proteins in MCF7 cell line were randomly selected and identified. MCF7 and SKBR3 cell lysates were subjected to two dimensional gel electrophoresis and spots of interest were identified by MALDI-TOF/TOF mass spectrometry. Upregulated proteins (≥2 fold and p value &amp;lt;0.05) in MCF7 cells were cellular retinoic acid binding-protein 2, Hsp27, nucleophosmin, electron transfer flavoprotein ≤ subunit, and profilin, and in SKBR3 cells were Rho GDP dissociation inhibitor-α (RhoGDI-α), voltage-dependent anion channel 2, aldehyde dehydrogeanase-2 (ALDH2), LDH- A, LDH-B, pyrophosphates 1, GAPDH, cathepsin D preprotein, and apolipoprotein A-I binding. Most of the identified proteins have been a candidate marker for cancer aggressiveness or drug resistance, but their differential expressions between SKBr3 and MCF7 cells were not known. Apo-lipoprotein binding-protein has not been described in cancer so far. Differential expression of RhoGDI-α was further validated by using western blotting with specific antibody. Further studies are required to clarify the importance of differential expressions of the identified proteins in SKBr3 and MCF7 breast cancer cell line models. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4785. doi:1538-7445.AM2012-4785
P219 FINE MAPPING OF THE BUTYROPHILIN GENOMICS REGION: ROLE IN HEPATITIS C VIRUS INFECTION (HCV)
Authors: L. Rojas, J. Ampuero, J.A. Del Campo, R.J. Garcia-Lozano, R. Solá, X. Forns, R. Moreno-Otero, R. Andrade, M. Diago, J. Salmeron, L. Rodrigo, J.A. Pons, J.M. Navarro, J.L. Calleja, J. Garcia-Samaniego, M. Buti, J. Crespo, C. Fernandez-Rodriguez, R. Millan, M.F. Gonzalez-Escribano, M. Romero-Gomez
Journal: Journal of Hepatology (2014)
Abstract 2927: Regulation of Na+/H+ exchanger 1 (NHE1) expression by hyperactivation of Akt in PTEN-null mouse embryonic fibroblasts
Authors: Joanne James, Jaspal Kaur Kumar, Marie Veronique Clement
Journal: Cancer Research (2011)

Abstract The serine/threonine kinase, Akt, plays a key role in regulating the signaling of a multitude of biological processes including cell proliferation, differentiation, migration and survival. In addition, many human cancers commonly display aberrant hyperactivated Akt survival pathway, a phenomenon that is frequent in tumours that have impaired or deletion of the PTEN tumour suppressor gene. Interestingly, we have recently demonstrated that an increase in intracellular O2− could replace the removal of growth factors resulting in the activation of Akt through the inhibition of the tumour suppressor PTEN and inducing an increased expression of the Na+/H+ exchanger 1 (NHE1), mimicking the phenotype of PTEN-null mouse embryonic fibroblasts. The Na+/H+ exchanger 1 (NHE1) is a membrane antiporter that has been described to promote cell survival via a dual mechanisms- defending cell volume and pHi through Na+/H+ exchange and by functioning as a scaffold for the recruitment of a signalplex involving, PI3-Kinase, ERM and Akt. In the present study, we asked whether the hyperactivity of Akt found in cells that have lost the expression of PTEN could influence the expression of NHE-1. We show that the PTEN-null mouse embryonic fibroblast model displayed an increased expression of Na+/H+ exchanger 1 (NHE1) and hyperactivated Akt compared to its PTEN wildtype counterpart. Moreover the half-life of NHE-1 was shown to increase in PTEN-null fibroblasts compared to the wildtype mouse embryonic fibroblasts. Hence, we hypothesized that Akt hyperactivation could influence the stability of NHE-1 expression. Indeed, using drugs such as LY294002 and Wortmannin to inhibit the activation of AKT, we showed that activated Akt had an effect on NHE-1 expression as the decrease in NHE-1 expression correlated with the dephosporylation of Akt, both at the mRNA and protein levels. Similarly, by silencing Akt gene expression, a more prominent decrease in NHE-1 protein expression was observed. Taken together, our data suggest that hyperactivated Akt may play a crucial role in the stability of NHE-1 in PTEN null fibroblasts, a phenomenon not observed in wildtype fibroblasts. Results from these studies could establish that Akt may be involved in the regulation of NHE-1 expression in tumours that have lost the expression of PTEN. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2927. doi:10.1158/1538-7445.AM2011-2927
TCTAP C-160 0/300 Re-stenting for Treatment of Bare Metal Stent Restenosis in a Patient with Adult Coarctation of Aorta
Authors: Jabar Ali, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Shaopeng Xu, Harris Ngow, Ji Bak Kim, Cheol Ung Choi, Eung Ju Kim, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2015)
B CELLS IN THE PATHOGENESIS OF THE OROFACIAL GRANULOMATOSIS/ORAL CROHN'S DISEASE SPECTRUM
Authors: P. Patel, F. Barone, L. Boursier, C. Nunes, Edward Odell, Michael Escudier, Stephen Challacombe, Jonathan Brostoff, Jo Spencer, J. Sanderson
Journal: Gut (2009)
FRI0373 Clinical Outcome of Dental Implant Therapy in Patients with SjÖGren's Syndrome
Authors: A. Vissink, A. Korfage, S. Arends, P. Meiners, A. Visser, F. Kroese, H. Bootsma
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Patients with Sjögren9s syndrome are subject to loss of teeth related to the high caries risk. Dental implant therapy is often considered as a proper possibility for prosthodontic rehabilitation of SS patients, but the clinical outcome of implant therapy in SS patients is yet not well assessed. <h3>Objectives</h3> To assess the clinical outcome of dental implant therapy in a cohort of well-classified patients with Sjögren9s syndrome (SS). <h3>Methods</h3> All SS patients regularly attending the University Medical Center Groningen for standardized follow-up in 2012-2013 (n=405) were asked by mail whether they were provided with dental implants. All patients met the revised American-European Consensus Group classification criteria for SS. Implant survival was noted. Periodontal indices and bone resorption were recorded clinically and radiographically. Patients9 symptoms, health-related quality of life (HR-QoL), oral functioning and satisfaction were assessed using validated questionnaires. <h3>Results</h3> Response rate was 82% (n=334). In total, 68 patients (20%) were provided with dental implants. In 50 out of these 68 patients clinical data could be collected. In these 50 patients, 144 endosseous implants had been inserted. Implant survival was 97%. Peri-implant tissues were healthy. Median marginal peri-implant bone loss was 0.7 mm (IQR 0.1-1.2). Patients were satisfied with their implant-retained prosthodontic rehabilitation, but oral functioning and chewing ability were impaired compared with healthy subjects. Worse oral functioning was associated with more dryness complaints, lower patients9 satisfaction and worse subjective chewing ability. <h3>Conclusions</h3> Implant therapy is a rather common phenomenon in SS patients as about one-fifth of the patients in our cohort of SS patients is provided with prosthodontic rehabilitation on dental implants. Considering the high implant survival, good peri-implant health, negligible marginal peri-implant bone loss and high patients9 satisfaction, dental implants are a good treatment option in prosthodontic rehabilitation of patients with SS. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4086
Abstract 4231: Epigenetic regulation and tumorigenicity of ovarian cancer cells
Authors: Fanliang Meng, Guiqin Sun, Zhong Li, Changping Zou, Molly A. Brewer
Journal: Cancer Research (2010)

Abstract Objective: The objective of this study was to investigate changes in CD133 expression and in tumorigenesis that occur in ovarian cancer cell lines treated with drugs that alter gene methylation. Materials and Methods: We selected two common drugs 5-aza-2′-deoxycytidine, a demethylating agent and Trichostain A(TSA), a histone deacetylase inhibitor and investigated three ovarian cancer cell lines(CD133+ cell lines A2780 and CD133- cell lines Hey and SKOV3) to determine their effect on ovarian cells in vitro and in vivo. Results: We demonstrated that epigenetic modification did not significantly alter cell viability but suppressed spheroid formation of cancer cells lines. FACS results indicated that the percentage of CD133+ cells increased following treatment with 5uM 5-aza-2′-deoxycytidine and 300nM trichostatin A after 72° incubation. Xenograft assay of the NOD/SCIDmice results demonstrated that both drugs reduced spheroid formation and blocked tumorigenesis. Conclusions: We concluded that 5-aza-2′-deoxycytidine and TSA can significantly suppress both spheroid formation and tumor formation and could be provide a new strategy for the treatment of resistant ovarian cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4231.
PWE-211 Longitudinal surveillance of submucosal tumours by endoscopic ultrasound: a single operator experience
Authors: T P Hong, A U Murugananthan, N Maqboul, J French, Q Arroyo, R Y Chen
Journal: Gut (2012)

<h3>Introduction</h3> Endoscopic ultrasound (EUS) provides increasingly improved assessment of submucosal tumours (SMT). The low yield of fine needle aspiration and the benign nature of the majority of lesions leave the optimal management for smaller, asymptomatic lesions unclear as further invasive procedures or surgery may be avoidable. Longitudinal studies characterising interval change of SMT are lacking and may provide information useful in optimising management. We report the experience of a single operator in the EUS surveillance of SMTs. <h3>Methods</h3> Patient cases were reviewed at two tertiary referral hospitals and one private hospital for patients who had serial EUS of the same lesion. EUS was performed by a single operator (RYC). For patients who had more than two EUS studies, details of the first and last were examined. Site, maximal diameter and layer of involvement were recorded. Paired data were analysed using a paired t-test with tests for correlation. <h3>Results</h3> 73 patients with SMT had at least two EUS procedures between February 2002 and October 2011. Lesions were found in the oesophagus (14), stomach (51) and duodenum (8) with involvement of the submucosa (40), deep submucosa/muscularis propria (4) and muscularis propria (29). The range between first and last EUS was 4–80 months. The lesions varied between 4 and 50 mm with a mean maximal diameter of 15.13 mm (95% CI 12.78 to 17.49) for the first EUS and 15.73 mm (95% CI 13.36 to 18.09) for the second EUS. Paired t-test analysis between the first and last measurements show that there was no significant difference (p=0.2321), with good correlation and effective pairing (r=0.9128, p&lt;0.0001). <h3>Conclusion</h3> In our study of submucosal tumours smaller than 50 mm, we showed no significant change in size on surveillance EUS. Further longitudinal studies are needed to determine optimal surveillance regimen for SMTs. <h3>Competing interests</h3> None declared.
Old Protein, New Function: VHL Tumor Suppressor Protein Inhibits Transcription
Authors: Nancy J. Nelson
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Old Protein, New Function: VHL Tumor Suppressor Protein Inhibits Transcription Get access Nancy J. Nelson Nancy J. Nelson Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 19, 4 October 1995, Pages 1432–1433, https://doi.org/10.1093/jnci/87.19.1432 Published: 04 October 1995
OP0042 Increased modeling-based bone formation and decreased bone resorption on endocortical surfaces in male cynomolgus monkeys treated with sclerostin antibody
Authors: M.S. Ominsky, Q.-T. Niu, H.Z. Ke
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Bone formation on previously quiescent surfaces occurs through a process known as bone modeling, which differs from the resorption-coupled formation that occurs during bone remodeling. The robust anabolic effects of sclerostin antibody (Scl-Ab) on trabecular surfaces were previously demonstrated to occur almost entirely via modeling in both OVX rats<sup>1</sup> and adolescent non-human primates.<sup>2</sup> <h3>Objectives</h3> In the current analysis, we quantified the effects of Scl-Ab on modeling- and remodeling-based bone formation on the femur endocortical surface in male cynomolgus monkeys. <h3>Methods</h3> Adolescent (4-5-year-old) monkeys were treated biweekly with subcutaneous vehicle (Veh) or 30 mg/kg Scl-Ab for 10 weeks. Tetracycline (25 mg/kg) was injected on days 14 and 24, and calcein (8 mg/kg) was injected on days 56 and 66. Histomorphometry was performed on cross-sections of the left femur diaphysis. <h3>Results</h3> Calcein-based mineralizing surface (MS/BS) was increased from 14% in Veh to 88% in the Scl-Ab group (p&lt;0.001). Bone forming surfaces were characterized as either modeling (MBF) or remodeling (RBF) surfaces based on the morphology of the underlying cement lines. The Scl-Ab-mediated increases in bone forming surface were almost entirely modeling-based, with an increase in MBF from 7% of the total bone surface in Veh to 77% in the Scl-Ab group (p&lt;0.001). No significant change was observed in RBF between the Veh and Scl-Ab groups (10% vs 15%, p=0.20), and no eroded surface was observed in any Scl-Ab-treated animal (vs 6% in Veh, p&lt;0.01). The period of bone formation on surfaces was extended in the Scl-Ab group, with 62% of calcein-labeled surfaces having both underlying tetracycline labels (active from day 14) as compared to only 4% in Veh (p&lt;0.001). Scl-Ab also increased osteoblast activity as reflected in mineral apposition rate (MAR) by 48% on modeling surfaces (1.18 vs 0.80 μm/day, p&lt;0.05), while remodeling MAR was not significantly changed. <h3>Conclusions</h3> These results demonstrate that Scl-Ab markedly increased modeling-based bone formation and reduced bone resorption in cortical bone, similar to the findings in trabecular bone. These contrasting effects on bone formation and resorption illustrate the unique tissue-level mechanism of Scl-Ab, which was consistent across both trabecular and cortical sites. Based on these results in non-human primates, the therapeutic profile of Scl-Ab provides a rapid and efficient process by which bone mass can be increased. <h3>References</h3> Li et al. J Bone Min Res. 2007;22(S1):S36. Ominsky et al. J Bone Min Res. 2010;25(S1):S53. <h3>Disclosure of Interest</h3> M. Ominsky Shareholder of: Amgen Inc., Employee of: Amgen Inc., Q.-T. Niu Shareholder of: Amgen Inc., Employee of: Amgen Inc., H. Z. Ke Shareholder of: Amgen Inc., Employee of: Amgen Inc.
Ebola survivors: not out of the woods yet
Authors: Jenny Harries, Michael Jacobs, Sally C Davies
Journal: BMJ (2016)

CMO’s advice on managing the risk of viral persistence and relapse

The recent outbreak of Ebola virus disease in west Africa was unprecedented in scale, with over 28 600 cases and 11 300 deaths.1 Survivors may have a range of continuing health problems, including viral persistence and disease recrudescence. If they present with illness, or for certain interventional procedures, they could put others at risk of infection. Clinicians therefore need to know what action to take, and here we lay out the current evidence and expert advice for England.

Studies of survivors from previous smaller outbreaks, corroborated recently, suggest that post-infection sequelae are not uncommon.2 3 4 5 Fatigue, arthralgia, and ocular complications (including uveitis) are particular problems. The pathogenesis of post-disease complications, and in particular the presence and role of viral persistence, is unknown.

It now seems that earlier prevalence studies underestimated the duration of viral persistence in several immune privileged body sites, such as the testes,6 eye, and central nervous system. A recent small observational study showed persisting Ebola virus genome in the semen of 26% of male survivors up to nine months after disease onset, much longer than the 91 days previously recognised.7 In one case, Ebola virus was detected in aqueous humour …
Serologic Evidence for Human Infection With Adenovirus-Associated Viruses
Authors: Neil R. Blacklow, M.D., M. David Hoggan, Sc.D., Wallace P. Rowe, M.D.
Journal: JNCI Journal of the National Cancer Institute (1968)

The adenovirus-associated viruses (AAV) are a newly recognized group of defective viruses that are capable of multiplying only in cell cultures infected with an adenovirus. Their natural history is unknown, since they have been identified only as contaminants of laboratory stocks of adenoviruses. This report describes the detection of antibodies to AAV serotypes 1, 2, and 3 in human sera by neutralization, complement fixation, and immunofluorescence tests. The curve of antibody frequency showed a steep rise between the ages of 1 and 10; about one-half of older children and adults showed antibodies to one or more AAV serotypes. AAV seroconversions were demonstrated by neutralizing and/or CF antibody in 5 of 12 children residing in a receiving home for young children in 1957–58 and in 7 of 28 children residing there in 1965–66. These findings therefore strongly indicate that man is naturally infected with viruses of the AAV group. Captive African green monkeys frequently showed antibody to AAV 4. Antibodies to all 4 AAV serotypes were found in a low proportion of captive but not in wild rhesus monkeys.
Abstract 4118: Fibroblast heterogeneity in oral squamous cell carcinoma is directed by tumor epithelium and promotes keratinocyte invasion <i>in vitro</i>
Authors: Kue Peng Lim, WenBin Wei, Kenneth Parkinson, Stephen Stewart Prime
Journal: Cancer Research (2010)

Abstract The transformation of human cells requires the accumulation of a broad spectrum of genetic abnormalities that typically lead to unrestrained cell growth. It has now become clear that alterations extrinsic to the tumor cell are also required and there is a considerable body of evidence to show that the cancer microenvironment plays a pivotal role in the initiation, progression and spread of cancer. In this study, we show that fibroblasts isolated from keratinocyte cultures of normal oral mucosa, epithelial dysplasia and mortal and immortal oral squamous cell carcinomas (OSCC) were heterogeneous and, using global gene expression profiling, could be grouped according to their tissue of origin. Fibroblasts from immortal OSCC, for example, showed high levels of activation and were characterized by down regulation of cell cycle-related genes and up-regulation of transmembrane-related genes. The data was validated using real time quantitative PCR to examine the expression of specific up-regulated (IGFBP7, ITGA6, p21) and down-regulated (FOXM1, MCM7) genes identified as having significant fold change in the expression analyses. Further, we examined the inter-relationship between tumor epithelial cells and tumor-associated fibroblasts. Whilst the proliferation of two target keratinocyte cell lines was stimulated by conditioned media from both normal and tumor-associated fibroblasts (in excess of keratinocyte growth in 10% serum), only fibroblasts from immortal OSCC stimulated the invasion of a non-tumorigenic keratinocyte cell line into fibroblast-rich collagen gels in organotypic cultures. Keratinocyte conditioned media stimulated the growth and activation of fibroblasts from normal oral mucosa and mortal OSCC. The results demonstrate a close inter-relationship between tumor epithelium and tumor-associated fibroblasts and show that the diversity of fibroblasts during tumor progression is not only influenced by the tumor epithelium but also, has biological significance in the promotion of tumor cell invasion in vitro. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4118.
681 HYPONATREMIA IN HOSPITALIZED PATIENTS WITH CIRRHOSIS: INTERIM DATA FROM AN OBSERVATIONAL, PROSPECTIVE, MULTI-CENTER, GLOBAL HYPONATREMIA REGISTRY INDICATES THAT HYPONATREMIA IS FREQUENTLY NOT TREATED
Authors: S. Sigal, A. Amin, J. Chiong, J. Dasta, A. Greenberg, J. Verbalis, S. Chase, K. Friend
Journal: Journal of Hepatology (2012)
Effect of treatment of patients with early-stage uterine carcinosarcoma
Authors: L. A. Cantrell, L. Havrilesky, D. O'Malley, M. Liotta, A. A. Secord, C. Nagel, A. N. Fader, A. Wallace, P. Rose, P. A. Gehrig
Journal: Journal of Clinical Oncology (2009)

5516 Background: The treatment of early stage uterine carcinosarcoma is controversial. We sought to retrospectively review factors that influence progression and survival. Methods: A retrospective, multi-institution study of women diagnosed from 1997–2007 was performed. Postoperative treatment included either observation (OBS), RT (brachytherapy, whole pelvic, or combination), chemotherapy (CT) alone or with RT (CT+RT). Data collected included time to recurrence, overall survival, and sites of recurrence. Statistics included ANOVA and Kaplan Meier. Results: One hundred and forty-six patients were diagnosed with early stage (stages 1 and 2) uterine carcinocarcoma. The median age at diagnosis was 68 years (range:40–91). The majority (62%) were Caucasian, 49 (34%) were African-American and the remainder were other ethnicities. One hundred and seventeen had stage 1 disease and 29 had stage 2. The majority of patients (N = 54, 37 %) were observed, 36 (25%) were treated with CT, 31 (21%) were treated with RT and 17 (12%) were treated with CT + RT. The median progression free survival (PFS) for patients diagnosed with early stage disease was 16.7 months for the OBS cohort and 38.2 months for the CT cohort (p &lt; 0.01). Median overall survival was 23 months for the OBS cohort and 39.3 months for the CT cohort (p = 0.02). The cohorts that underwent RT or CT+RT had improved median progression free (29.9, 20 months) and overall survival (31.7, 20.8 months) as compared to the OBS cohort, however this was not a statistically significant difference. Conclusions: We report on the largest experience in the literature on early stage uterine carcinosarcoma and the first to show that women with early stage disease may benefit from adjuvant chemotherapy. The role of radiation therapy or combination chemotherapy and radiation could not be adequately assessed from this retrospective analysis, but a trend toward improved survival was present. Prospective trials evaluating the best treatment for patients with early stage carcinosarcoma of the uterus should be undertaken to better answer this question. No significant financial relationships to disclose.